Yonsei Med J.  2020 Jan;61(1):56-63. 10.3349/ymj.2020.61.1.56.

Effect of Dialysis on Aryl Hydrocarbon Receptor Transactivating Activity in Patients with Chronic Kidney Disease

Affiliations
  • 1Department of Internal Medicine, Nowon Eulji University Hospital, Seoul, Korea. leesy1146@eulji.ac.kr
  • 2Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
  • 3Department of Physiology, College of Medicine, Kyung Hee University, Seoul, Korea. ykpak@khu.ac.kr

Abstract

PURPOSE
Elevated aryl hydrocarbon receptor (AhR) transactivating (AHRT) activity and uremia in chronic kidney disease (CKD) may interact with each other, further complicating the disease course. In this study, we prospectively estimated serum AHRT activity using a highly sensitive cell-based AhR-dependent luciferase activity assay in CKD patients and compared differences therein according to treatment modality.
MATERIALS AND METHODS
Patients undergoing peritoneal dialysis (PD) (n=22) and hemodialysis (HD) (n=38) and patients with pre-dialysis CKD stage IV or V (n=28) were included. AHRT activity and intracellular adenosine triphosphate (ATP) levels were measured. We performed a correlation analysis for AHRT activity, ATP levels, and various clinical parameters.
RESULTS
AHRT activity and intracellular ATP levels were inversely correlated and differed according to treatment modalities. AHRT activity was higher in non-dialysis CKD patients than in patients undergoing dialysis and was higher in patients undergoing HD, compared to PD. AHRT activity decreased after HD treatment in HD patients. ATP levels were higher in healthy controls than in patients with pre-dialysis CKD and PD and were further decreased in patients with HD. We noted significant correlations between multiple clinical parameters associated with cardiovascular risk factors and AHRT activity.
CONCLUSION
AHRT activity was elevated in CKD patients, while dialysis treatment reduced AHRT activity. Further studies are warranted to specify AHRT activity and to evaluate the precise roles thereof in patients with CKD.

Keyword

Aryl hydrocarbon receptor transactivating activity; chronic kidney disease; dialysis

MeSH Terms

Adenosine Triphosphate
Dialysis*
Humans
Luciferases
Peritoneal Dialysis
Prospective Studies
Receptors, Aryl Hydrocarbon*
Renal Dialysis
Renal Insufficiency, Chronic*
Risk Factors
Uremia
Adenosine Triphosphate
Luciferases
Receptors, Aryl Hydrocarbon
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr